前往化源商城

321-01-7 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3406312
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2015
Volume: 25
Issue: 7
First Page: 1412
Last Page: 1416
DOI: 10.1016/j.bmcl.2015.02.048
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
49.86IC50=49860nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3406310
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2015
Volume: 25
Issue: 7
First Page: 1412
Last Page: 1416
DOI: 10.1016/j.bmcl.2015.02.048
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3406311
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2015
Volume: 25
Issue: 7
First Page: 1412
Last Page: 1416
DOI: 10.1016/j.bmcl.2015.02.048
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
0.07IC50=70nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1026725
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1998
Volume: 61
Issue: 1
First Page: 2
Last Page: 7
DOI: 10.1021/np970343j
Standard TypeStandard RelationStandard Value
Ratio IC50=117
Ratio IC50>15
Ratio IC50<0.5
Ratio IC50=57
Ratio IC50=96
Ratio IC50=21
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1026722
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1998
Volume: 61
Issue: 1
First Page: 2
Last Page: 7
DOI: 10.1021/np970343j
Standard TypeStandard RelationStandard Value
Ratio IC50=518
Ratio IC50>1
Ratio IC50=28
Ratio IC50=3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aldo-keto reductase family 1 member B1
External ID: CHEMBL986728
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 9
First Page: 1191
Last Page: 1196
DOI: 10.1021/np0301543

Target ChEMBL ID: CHEMBL2622
ChEMBL Target Name: Aldose reductase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=19%
Inhibition=41%
Inhibition=38%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1942347
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg Med Chem Lett
Year: 2012
Volume: 22
Issue: 2
First Page: 1099
Last Page: 1102
DOI: 10.1016/j.bmcl.2011.11.109
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
IC50>10ug.mL-1
8.91IC50=8910nM
3.45IC50=3450nM
9.03IC50=9030nM
IC50>10ug.mL-1
IC50>10ug.mL-1
IC50>10ug.mL-1
IC50>10ug.mL-1
IC50>10ug.mL-1
IC50>10ug.mL-1
6.93IC50=6930nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020950
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=19.9%
Activity=19.4%
Activity=17.9%
Activity=21.9%
Activity=18.3%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020949
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=21%
Activity=19.5%
Activity=17.6%
Activity=18.4%
Activity=16.8%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020956
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=16.7%
Activity=15.9%
Activity=13.3%
Activity=17%
Activity=20.1%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020955
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=13.4%
Activity=17.7%
Activity=13.9%
Activity=17.4%
Activity=17.3%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4710189
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2020
Volume: 208
First Page: 112754
Last Page: 112754
DOI: 10.1016/j.ejmech.2020.112754
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.67IC50=670nM
18IC50=18000nM
50IC50=50000nM
19IC50=19000nM
50IC50>50000nM
9IC50=9000nM
0.96IC50=960nM
16IC50=16000nM
50IC50>50000nM
0.072IC50=72nM
0.87IC50=870nM
3.3IC50=3300nM
13IC50=13000nM
0.76IC50=760nM
1.5IC50=1500nM
1.4IC50=1400nM
31IC50=31000nM
50IC50>50000nM
50IC50>50000nM
50IC50>50000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1020957
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004
Standard TypeStandard RelationStandard ValueStandard Units
Activity=127U/L
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020952
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=22.1%
Activity=20.6%
Activity=16.5%
Activity=21.2%
Activity=22.4%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020951
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=18.6%
Activity=20.6%
Activity=17.6%
Activity=21.2%
Activity=21%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020954
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=17.5%
Activity=15.3%
Activity=16.8%
Activity=18.1%
Activity=14.3%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatocyte
External ID: CHEMBL1020953
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL613362
ChEMBL Target Name: Hepatocyte
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=19%
Activity=16.7%
Activity=16.3%
Activity=15.5%
Activity=13.5%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4275212
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2018
Volume: 157
First Page: 729
Last Page: 742
DOI: 10.1016/j.ejmech.2018.08.008
Standard TypeStandard RelationStandard ValueStandard Units
DIZ=2mm3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Alanine aminotransferase 1
External ID: CHEMBL1020960
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1987
Volume: 50
Issue: 4
First Page: 612
Last Page: 617
DOI: 10.1021/np50052a004

Target ChEMBL ID: CHEMBL5929
ChEMBL Target Name: Alanine aminotransferase 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Activity=103U/L
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1007797
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1994
Volume: 57
Issue: 1
First Page: 42
Last Page: 51
DOI: 10.1021/np50103a006
Standard TypeStandard RelationStandard ValueActivity Comment
TI=4
TI=1
TI=3
TI=1
TI=9
TI=1
TINot Determined
TI=1
TI=2
TI=1
TI=2
TI=2
TI=1
TINot Determined
TI=1
TI=4
TINot Determined
TI<1
TI=4
TI=3
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cryptococcus neoformans
External ID: CHEMBL4668795
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Nat Prod
Year: 2020
Volume: 83
Issue: 7.0
First Page: 2261
Last Page: 2268
DOI: 10.1021/acs.jnatprod.0c00395

Target ChEMBL ID: CHEMBL365
ChEMBL Target Name: Cryptococcus neoformans
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
107.7MIC=107700nM
252.5MIC=252500nM
5.4MIC=5400nM
MICNot Determined
83.3MIC=83300nM
MICNot Determined
MICNot Determined
113.1MIC=113100nM
MICNot Determined
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cryptococcus neoformans
External ID: CHEMBL4668794
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Nat Prod
Year: 2020
Volume: 83
Issue: 7.0
First Page: 2261
Last Page: 2268
DOI: 10.1021/acs.jnatprod.0c00395

Target ChEMBL ID: CHEMBL365
ChEMBL Target Name: Cryptococcus neoformans
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
53.9MIC=53900nM
126.2MIC=126200nM
5.4MIC=5400nM
2.6MIC=2600nM
20.8MIC=20800nM
10.7MIC=10700nM
1.8MIC=1800nM
113.1MIC=113100nM
27MIC=27000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Candida albicans
External ID: CHEMBL4668796
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Nat Prod
Year: 2020
Volume: 83
Issue: 7.0
First Page: 2261
Last Page: 2268
DOI: 10.1021/acs.jnatprod.0c00395

Target ChEMBL ID: CHEMBL366
ChEMBL Target Name: Candida albicans
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
107.7MIC>107700nM
252.5MIC>252500nM
86.5MIC>86500nM
324.6MIC>324600nM
83.3MIC>83300nM
689.5MIC>689500nM
56.6MIC=56600nM
56.6MIC=56600nM
432.8MIC>432800nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Entamoeba histolytica
External ID: CHEMBL2434624
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2013
Volume: 76
Issue: 10
First Page: 1970
Last Page: 1975
DOI: 10.1021/np400606g

Target ChEMBL ID: CHEMBL612853
ChEMBL Target Name: Entamoeba histolytica
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
IC50=54.2ug.mL-1Outside typical range
IC50=0.04ug.mL-1
IC50=65.6ug.mL-1Outside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Giardia intestinalis
External ID: CHEMBL2434623
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2013
Volume: 76
Issue: 10
First Page: 1970
Last Page: 1975
DOI: 10.1021/np400606g

Target ChEMBL ID: CHEMBL612652
ChEMBL Target Name: Giardia intestinalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
IC50=68.9ug.mL-1Outside typical range
IC50=0.21ug.mL-1
IC50=33.9ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL3376034
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg Med Chem Lett
Year: 2015
Volume: 25
Issue: 2
First Page: 327
Last Page: 332
DOI: 10.1016/j.bmcl.2014.11.039

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.007IC50=7nM
2.4IC50=2400nM
6IC50=6000nM
0.007IC50=7nM
0.071IC50=71nM
0.079IC50=79nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL3376036
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg Med Chem Lett
Year: 2015
Volume: 25
Issue: 2
First Page: 327
Last Page: 332
DOI: 10.1016/j.bmcl.2014.11.039

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.077IC50=77nM
5.3IC50=5300nM
5.9IC50=5900nM
0.013IC50=13nM
0.079IC50=79nM
0.08IC50=80nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL3376035
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg Med Chem Lett
Year: 2015
Volume: 25
Issue: 2
First Page: 327
Last Page: 332
DOI: 10.1016/j.bmcl.2014.11.039

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.02IC50=20nM
2.9IC50=2900nM
6.7IC50=6700nM
0.009IC50=9nM
0.065IC50=65nM
0.069IC50=69nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL838986
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2004
Volume: 14
Issue: 2
First Page: 463
Last Page: 466
DOI: 10.1016/j.bmcl.2003.10.038
Standard TypeStandard RelationStandard Value
Relative IC50=2.55
Relative IC50=0.37
Relative IC50=2.42
Relative IC50=4.71
Relative IC50=3.66
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Chromobacterium violaceum
External ID: CHEMBL4266102
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2017
Volume: 131
First Page: 255
Last Page: 262
DOI: 10.1016/j.ejmech.2017.03.018

Target ChEMBL ID: CHEMBL613862
ChEMBL Target Name: Chromobacterium violaceum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
IZ=2mm
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Penicillium sp.
External ID: CHEMBL3058525
Protocol: N/A
Comment: Journal: J Agric Food Chem
Year: 2004
Volume: 52
Issue: 5
First Page: 1077
Last Page: 1082
DOI: 10.1021/jf040453d

Target ChEMBL ID: CHEMBL613245
ChEMBL Target Name: Penicillium sp.
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityActive
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aspergillus niger
External ID: CHEMBL3058526
Protocol: N/A
Comment: Journal: J Agric Food Chem
Year: 2004
Volume: 52
Issue: 5
First Page: 1077
Last Page: 1082
DOI: 10.1021/jf040453d

Target ChEMBL ID: CHEMBL358
ChEMBL Target Name: Aspergillus niger
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityActive
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:
External ID: HMS1303
Protocol: Prior to screening, lyophilized FITC-GIV peptide (a.a. 1671-1701) is dissolved in 100% DMSO to a concentration of 0.5 mM, then further diluted with water to a final concentration of 50 microM. One stock was prepared in batch for the entire screen and aliquoted. All protein stocks were stored at -80C. Thawing of aliquots on the day of the assay was performed rapidly at room temperature.

Prior to transfer of screening compounds, experimental wells of 384-well assay plates were pre-filled with 37.8 nM of FITC-GIV peptide (for 25 nM final concentration) in a 10 microL volume of assay buffer (50 mM Tris [pH 7.4], 100 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 0.4% NP-40, 30 microM GDP, 1 mM DTT). Control wells were pre-filled with 37.8 nM of FITC-GIV peptide in 10 microL of assay buffer containing either 1% DMSO (vehicle negative control) or 45.3 microM AlCl3+15.1 mM NaF (AlF4- positive control). Each plate contained 16 negative control and 16 positive control wells. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface. Following, 100 nL of experimental compound was pin-transferred into individual wells for each of two replicate assay plates (A&B). After pin-transfer, 5 microL of 3 microM His-tagged rat Galphai3 purified from E. coli (for 1 microM final concentration) was added to each well, and assay plates were shaken at low speed for 5 seconds. Final assay volume was 15 microL. Plates were centrifuged at 1000xg for 2 minutes to eliminate bubbling on the surface and shaken for 10 seconds prior to an incubation of 90 minutes at room temperature. Plates were protected from prolonged light exposure. All manipulations were performed at room temperature.

Assay plates were read with a PerkinElmer Wallac EnVision Multilabel 2103 plate reader using the fluorescent polarization measurement technology with a D505fp/D535 dual mirror and a 480 nm excitation filter. 535 nm emission filters were used for P and S channel reads at 11 mm measurement height with 30 flashes and detector gains of 319 and 563. G-factor 0.96.

Negative control: DMSO
Positive control: Aluminum tetrafluoride (AlF4-, composite of NaF and AlCl3)
Comment: Calculated result values and scoring of active compounds:

Z-score: Indicates the number of standard deviations an experimental condition is from the mean. It is calculated based on plate average (u) and standard deviation (s) of experimental well fluorescence polarization (FP) measurements for each replicate. Z-score (z) is defined as the quotient of the mean of the experimental well population subtracted from an individual well's FP (x), divided by the standard deviation within the experimental wells; z = (x-u)/s.

Normalized percent control: calculated by subtracting plate average positive control FP from experimental well FP, dividing by the difference between plate average negative and positive control FP, and multiplying by 100.

STD: the number of standard deviations from the plate average negative control FP for each replicate experimental well

Compound wells with FP values exceeding +5 standard deviations from the negative control sample average were flagged as potential aggregators or fluorescence quenchers due to their high polarization signal (HighPol) and were excluded from further consideration. Activity scores were calculated by averaging the replicate normalized percent of control values and subtracting from 100 (score based on single replicate if data for other replicate was excluded for any reason). Result values < 0 were set to 0 (no activity) and > 100 were set to 100 (100% activity). Compounds with activity score >= 15 were considered active.
mP_AFluorTotal_APchan_ASchan_AmP_BFluorTotal_BPchan_BSchan_BZ-score_AZ-score_BPercent Ctrl_APercent Ctrl_BSTD_ASTD_BNote: Polarization Artifact
122.41957988860658427448204128.11963767260572207523232-1.18225-0.63523293.2647101.541-1.80030.362745
124.61958252660565717469384129.81962517560450197535137-0.634716-0.19961197.3807104.669-0.7001171.09906
124.21966389660838267496244126.21969903460848867529262-0.734268-1.122196.632498.0451-0.90015-0.460198
1231973179861103407511118126.71971411360873537539407-1.03292-0.99397994.387398.965-1.50025-0.243634
128.11989636061370667622228130.519724618607261775793840.236366-0.0202377103.929105.9571.050181.40225
125.61986771661402087587300131.31967349360531227567249-0.3858350.1847699.2516107.429-0.2000331.74875
127.72002396861782517667466128.819866494612424676180020.136814-0.455859103.181102.8290.8501420.665934
129.21961772360456307526463132.719789155608172076257150.5101340.543507105.987110.0051.600272.35513
130.91974707560775087592059133.819696771604822176003290.9332310.82538109.167112.0292.450412.83157
127.41995714661589967639154131.119907155612592276553110.06214940.133511102.619107.0610.7001171.66213
128.61970436060754757553410127.919896451613799676204590.360806-0.686482104.864101.1731.300220.276119
126.51975466161009937552675131.21981143860959967619446-0.1618430.159136100.935107.2450.2500421.70544
125.21989803761513307595377128.51982052261116137597296-0.485388-0.53273398.5033102.277-0.4000670.535996
125.21974444761039237536601130.11961319460400397533116-0.485388-0.12273798.5033105.221-0.4000671.229
127.41996280061609707640860131.319894559612117976522010.06214940.18476102.619107.4290.7001171.74875
128.82002040261715807677242132.519888130611339976613320.4105820.492258105.239109.6371.400232.26851
128.31997122561589057653415131.820071564617330377249580.2861420.312884104.303108.3491.150191.96532
128.7197498216088940757194112919670633606278775450590.385694-0.404609105.051103.1971.350230.752559
125.719727542609617775351881291962415560487067526743-0.360947-0.40460999.4387103.197-0.1500250.752559
127.82004995261859487678056130.820021937616251676969050.1617020.0566366103.368106.5090.900151.53219
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:RecName: Full=G-protein coupled receptor 151; AltName: Full=G-protein coupled receptor PGR7; AltName: Full=GPCR-2037; AltName: Full=Galanin receptor 4; AltName: Full=Galanin-receptor-like protein; Short=GalRL
External ID: GPR151_PHUNTER_AG_LUMI_1536_1X%ACT
Protocol: Assay Overview:
TThe goal of this NIH sponsored research project was to identify GPR151 agonists via high-throughput screening (HTS) efforts. In brief, the McDonald Lab transferred the GPR151 AG 384wpf assay to Scripps for implementation and miniaturization to 1,536-well format followed by screening against the Scripps Drug Discovery Library (SDDL). A counterscreen assay, employing GPR119 cells, was also implemented by Scripps to identify compounds that non-specifically affect the PathHunter detection method. This project was aided by cheminformatic efforts to help identify compounds that demonstrated authentic agonist pharmacology and non-promiscuous activity profiles across other primary screens run against the SDDL. At completion of the project, several compounds demonstrated activity in the GPR151 AG PathHunter assay. All compounds selected for titration were also subjected to LC-MS analysis to confirm mass and sample purity

Protocol Summary:
Prior to the start of the assay, cells were resuspended in growth media at 2000cells/well in 1536 well plates. This was followed by an incubation of 18 hours at 37C+5%CO2. Then 1uL of Opti-Mem added to all wells except high controls to which 3X EA reagentwas added to each of those wells (0.2X final in lysis buffer). Compounds were pinned at 11.20uM final concentration in 1.0% DMSO followed by a 90 minute incubation at 37C+5%CO2. At this stage 3uL of Promega Beta-Glo detection Buffer was added to all wells followed by a 1 hour incubation at room temperature. Finally the assay end point read was taken using the ViewLux imaging reader from PerkinElemer Lifesciences with a 5 second exposure. Raw assay data was imported into Scripps# corporate database and ascetrained for Z' greater than 0.5 in order to be processed futher.

The percent activation for each compound was calculated as follows:

Percent Response of compound= 100 * ((Test Well-Median Data Wells)/(Median High Control # Median Data Wells))
Where:
Test_Well is defined as wells containing GPR151 cells in the presence of test compound
High_Control represents wells containing GPR151 cells stimulated with 0.2X EA reagent
Low_Control is defined as wells containing GPR151 cells and DMSO
PubChem Activity Outcome and Score:
Standard Cutoff
The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.
The activity score range for active compounds is 100-1, for inactive 1-0.
List of Reagents:
GPR151 cells (supplied by Patricia McDonald)
Pen Strep (Invtirogen 15140)
FBS (Invtirogen 16140)
Hygromycin (Invtirogen 10687010)
Lysis buffer (CisBio 62CL2FDF)
EA Reagent (DiscoverX 30-411)
G418 (Gemini Bio 400-113)
Opti-MEM (Invtirogen 31985)
Trypsin (Invtirogen 15400054)
Beta Glo (Promega E4780)
1536-well plates (Greiner Bio-One, part 789173)
Comment: Due to the size of the Scripps Molecular Screening Center compound library, this assay have been run as multiple separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the Scripps Molecular Screening Center.

A mathematical algorithm was used to determine what we call the standard hit cut-off to identify active compounds. Two values were calculated: (1) the average percent activation of all compounds tested in the screen, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater percent activation than the cutoff parameter was declared active. Using this "Standard Cutoff" (= 4.91%) the primary assay yielded 6,756 active compounds ("hits")."
Activation at 11.2 uM
25.9791
24.6001
23.5536
22.7312
22.7177
22.1764
22.1331
21.3196
20.9399
20.5357
19.9724
19.7958
19.6966
19.0437
18.6511
18.5926
18.5486
18.5244
18.4073
18.3393
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3365150
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 17
First Page: 4286
Last Page: 4290
DOI: 10.1016/j.bmcl.2014.07.022

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Survival=29.7%
ActivityActive
Survival=4.3%
Survival=46.8%
ActivityActive
Survival=45.8%
Survival=55.7%
Survival=58.9%
Survival=48.3%
Survival=47%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Fusarium oxysporum
External ID: CHEMBL3058527
Protocol: N/A
Comment: Journal: J Agric Food Chem
Year: 2004
Volume: 52
Issue: 5
First Page: 1077
Last Page: 1082
DOI: 10.1021/jf040453d

Target ChEMBL ID: CHEMBL612648
ChEMBL Target Name: Fusarium oxysporum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityActive
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Trichoderma viride
External ID: CHEMBL3058528
Protocol: N/A
Comment: Journal: J Agric Food Chem
Year: 2004
Volume: 52
Issue: 5
First Page: 1077
Last Page: 1082
DOI: 10.1021/jf040453d

Target ChEMBL ID: CHEMBL612873
ChEMBL Target Name: Trichoderma viride
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityActive
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active